💬 Income investors: Is Pfizer’s 6.4% dividend too good to be true? Are you betting on its pipeline comeback?
Over the past five years, $Pfizer(PFE)$ shares have tumbled 25%, while the S&P 500 surged 68%.
As patents on key drugs expired, uncertainty around future growth mounted and investor confidence eroded. For a time, the dividend was the only clear reason to own Pfizer stock.
This year, however, rising market risk aversion has sent money flooding into high-dividend stocks.
With a 6.4% dividend yield, Pfizer has re-emerged as a top choice for investors — and its stock is quietly staging a breakout not seen in years: outperforming the S&P 500.
The last time Pfizer beat the broader market was 2022, when it fell 13% while the S&P 500 plunged 19% amid high inflation.
From 2023 to 2025, the stock suffered deep declines: –44%, –8%, and –6%, respectively.
In a growth-dominated market, skepticism toward Pfizer’s outlook left it deeply out of favor.
This year’s environment echoes 2022: economic worries, rising commodity prices, and geopolitical conflicts have pushed investors toward defensive assets.
Pfizer, with its generous 6.4% yield, has been a prime beneficiary.
Recently, the pharmaceutical giant released positive clinical trial results that further boosted sentiment, driving the stock up roughly 3% in a single day.
After years of underperformance, markets are asking: Can Pfizer’s rebound last?
Positive Progress, Cautious Outlook
On March 17, Pfizer announced promising Phase 2 results for atirmociclib in second-line metastatic breast cancer.
When combined with fulvestrant (Faslodex), the candidate significantly extended progression-free survival compared with fulvestrant alone or alternative combinations.
Notably, atirmociclib has a distinct mechanism of action from current standard therapies, with favorable efficacy and manageable safety in Phase 2.
Still, the drug remains in mid-stage development and requires successful Phase 3 trials before potential approval. Overall survival data are immature and not yet disclosed.
While atirmociclib delivered positive results in second-line patients, Pfizer’s long-term commercial strategy favors earlier-line use — so the direct link to future sales is not perfectly straightforward.
Even so, the results send a clear positive signal for a company desperate to rebuild its pipeline and financial profile.
Deep Pipeline & Attractive Valuation Support Long-Term Case
Year-to-date, Pfizer has unveiled multiple clinical updates, including:
-
atirmociclib (breast cancer)
-
tilrekimig (potential eczema treatment, not yet US-approved)
-
label expansion for the approved cancer drug Talzenna
Management revealed plans to initiate approximately 20 pivotal clinical trials in 2026, following 11 launches in 2025.
Its oncology portfolio and weight-loss pipeline are key focus areas.
Over the next two years, major clinical catalysts are expected to support the stock and drive portfolio expansion, revenue, and profit growth.
On valuation:
Pfizer trades at a forward P/E ratio of just 9.2x, well below the healthcare sector average of 16.9x, creating a meaningful valuation advantage.
Analysts emphasize that Pfizer’s investment case rests on more than one Phase 2 win.
Its deep clinical pipeline and reasonable valuation are the more compelling pillars for long-term investors.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
Comments